Immunovia AB
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Immunovia AB (0G8X) - Total Assets
Latest total assets as of December 2025: Skr88.21 Million SEK
Based on the latest financial reports, Immunovia AB (0G8X) holds total assets worth Skr88.21 Million SEK as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Immunovia AB - Total Assets Trend (2012–2025)
This chart illustrates how Immunovia AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Immunovia AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Immunovia AB's total assets of Skr88.21 Million consist of 91.2% current assets and 8.9% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 87.8% |
| Accounts Receivable | Skr2.83 Million | 3.2% |
| Inventory | Skr119.00K | 0.1% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Immunovia AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Immunovia AB's current assets represent 91.2% of total assets in 2025, an increase from 26.1% in 2012.
- Cash Position: Cash and equivalents constituted 87.8% of total assets in 2025, up from 23.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 73.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 3.2% of total assets.
Immunovia AB Competitors by Total Assets
Key competitors of Immunovia AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
Immunovia AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Immunovia AB generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Immunovia AB is currently not profitable relative to its asset base.
Immunovia AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.42 | 1.34 | 13.28 |
| Quick Ratio | 3.42 | 1.34 | 13.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr56.93 Million | Skr 7.20 Million | Skr 400.56 Million |
Immunovia AB - Advanced Valuation Insights
This section examines the relationship between Immunovia AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 167.0% |
| Total Assets | Skr88.21 Million |
| Market Capitalization | $297.15K USD |
Valuation Analysis
Below Book Valuation: The market values Immunovia AB's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Immunovia AB's assets grew by 167.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Immunovia AB (2012–2025)
The table below shows the annual total assets of Immunovia AB from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr88.21 Million | +166.97% |
| 2024-12-31 | Skr33.04 Million | -66.52% |
| 2023-12-31 | Skr98.68 Million | -67.17% |
| 2022-12-31 | Skr300.59 Million | -39.13% |
| 2021-12-31 | Skr493.81 Million | -25.31% |
| 2020-12-31 | Skr661.18 Million | +57.66% |
| 2019-12-31 | Skr419.37 Million | -12.15% |
| 2018-12-31 | Skr477.38 Million | +90.37% |
| 2017-12-31 | Skr250.77 Million | -11.52% |
| 2016-12-31 | Skr283.41 Million | +209.71% |
| 2015-12-31 | Skr91.51 Million | +135.40% |
| 2014-12-31 | Skr38.87 Million | +420.70% |
| 2013-12-31 | Skr7.47 Million | +149.05% |
| 2012-12-31 | Skr3.00 Million | -- |